Brief: Brii Biosciences Says Co's Amubarvimab/Romlusevimab Combination Therapy Retains Neutralizing Activity Against Omicron Ba.2 Sars-Cov-2 Subvariant
09/05/2022 13:19
May 9 (Reuters) - Brii Biosciences Ltd 2137.HK :
* CO' S AMUBARVIMAB/ROMLUSEVIMAB COMBINATION THERAPY RETAINS
NEUTRALIZING ACTIVITY AGAINST OMICRON BA.2 SARS-COV-2 SUBVARIANT
Source text for Eikon: ID:nHKS3n5Tl4
Further company coverage: 2137.HK
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR